Federation Francophone De Cancerologie Digestive

This Phase 3 trial tests whether adding fruquintinib to the standard drug trifluridine/tipiracil helps people with advanced stomach or gastro-esophageal cancer live longer. About 324 participants who have already tried at least two prior treatments will receive either the combo o…

This study is testing whether giving two drugs (encorafenib and cetuximab) before surgery can shrink tumors in people with a specific genetic mutation (BRAF V600E) in colon or upper rectal cancer. About 30 participants will receive the drugs for 6 weeks before their planned surge…

This phase 3 trial tests whether giving a specific chemotherapy combination (mDCF) before standard chemoradiotherapy can improve outcomes for people with locally advanced anal cancer. About 310 adults with stage T3-4 or N1 anal cancer will be randomly assigned to either standard …

This study tracks 300 adults with advanced colorectal cancer who are taking the drug fruquintinib. Researchers want to find out which patient or tumor features help the drug work best and improve survival. The goal is to learn from real-world use to better match patients with eff…

This study will follow 600 people with a specific type of advanced colorectal cancer (MSI-high) who are being treated with the immunotherapy drug pembrolizumab. The goal is to understand why about 20-30% of patients do not respond to this treatment. By analyzing tumor samples and…